Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF)(“Microbix®” or the “Company”), a life sciences innovator, manufacturer, and exporter, is pleased to announce the results of the Annual and Special Meeting of Shareholders held on March 29, 2023.
Shareholders voted on a range of important issues, from strategic initiatives to new plans for the future. With the support of its shareholders, the Company is now positioned to continue its mission of delivering innovative life sciences solutions.
At the Meeting, an impressive 48.77% of the issued and outstanding shares were present and voted in favour of all the proposals outlined in the Management Information Circular (the “Circular”) dated February 17, 2023. It was a successful day all round!
The nominees listed in the Circular have been overwhelmingly re-elected as directors of Microbix, ensuring that the same faces will continue to lead the company forward.
At the Annual General Meeting, shareholders gave their resounding approval to the Company’s re-appointment of Ernst & Young LLP as auditors, with an overwhelming 99.80% of the votes cast in favour.
About Microbix Biosystems
Microbix is a leader in the global diagnostics industry, leveraging its expertise to create cutting-edge biological products for human health. With a team of over 100 skilled professionals, the company has achieved annualized sales of C$2.0 million per month. From antigens for immunoassays to its laboratory quality assessment products (QAPs™), Microbix’s products are used by more than 100 diagnostics makers and are now available in over 30 countries.
As an ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered and Health Canada establishment licensed company, Microbix is committed to providing the highest quality products and services.
Through the help of its distributors, including 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution SpA., Labquality Oy, The Medical Supply Company of Ireland, Neo-Science Equipment LLC, R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc., and Thomas Scientific LLC., Microbix is able to provide CE marked products to its customers.
Microbix, a leading biotechnology company headquartered in Mississauga, Ontario, Canada and traded on the TSX and OTCQX, applies its biological expertise and infrastructure to develop proprietary products and technologies for the molecular diagnostic testing industry.
The company’s flagship products include viral transport medium (DxTM™) and Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots. With its cutting-edge solutions, Microbix is at the forefront of the industry, providing innovative solutions to help laboratories streamline their operations.